Cargando…

BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression

Paclitaxel (PTX) is commonly used to treat urothelial carcinoma (UC) after platinum-based chemotherapy has failed. However, single-agent taxane therapy is not sufficient to inhibit tumor progression and drug resistance in advanced UC. Epithelial-to-mesenchymal transition (EMT) induced by fibroblast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Se Hyun, Ryu, Haram, Ock, Chan-Young, Suh, Koung Jin, Lee, Ji Yun, Kim, Ji-Won, Lee, Jeong-Ok, Kim, Jin Won, Kim, Yu Jung, Lee, Keun-Wook, Bang, Soo-Mee, Kim, Jee Hyun, Lee, Jong Seok, Ahn, Joong Bae, Kim, Kui-Jin, Rha, Sun Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214101/ https://www.ncbi.nlm.nih.gov/pubmed/30326563 http://dx.doi.org/10.3390/ijms19103164

Ejemplares similares

Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells
por: Boichuk, Sergei, et al.
Publicado: (2022)

Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures
por: Kähkönen, T. E., et al.
Publicado: (2020)

Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma
por: Kim, Young Saing, et al.
Publicado: (2018)

Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing
por: Hyung, Sujin, et al.
Publicado: (2022)

Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion
por: Kim, Sun Young, et al.
Publicado: (2017)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer
por: Kim, Kui-Jin, et al.
Publicado: (2020)

FGFR1 is amplified during the progression of in situ to invasive breast carcinoma
por: Jang, Min Hye, et al.
Publicado: (2012)

Semi-Automated Cell Panning for Efficient Isolation of FGFR3-Targeting Antibody
por: Min, Byeongkwi, et al.
Publicado: (2021)

Dizygotic twin sisters with normosmic idiopathic hypogonadotropic hypogonadism caused by an FGFR1 gene variant
por: Choe, Jaewon, et al.
Publicado: (2020)

Role of FGFR3 in Urothelial Carcinoma
por: Akanksha, Malik, et al.
Publicado: (2019)

Complexity of FGFR signalling in metastatic urothelial cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro
por: Cha, Yongjun, et al.
Publicado: (2018)

Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations
por: Lima, Nadia Carvalho, et al.
Publicado: (2020)

Hematopoietic stem cell regulatory volumes as revealed in studies of the bgj/bgj:W/WV chimera
Publicado: (1978)

The FGFR Family Inhibitor AZD4547 Exerts an Antitumor Effect in Ovarian Cancer Cells
por: Na, Yu Ran, et al.
Publicado: (2021)

Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
por: Benjamin, David J, et al.
Publicado: (2022)

Pathological and Prognostic Impacts of FGFR2 Overexpression in Gastric Cancer: A Meta-Analysis
por: Kim, Hyeong Su, et al.
Publicado: (2019)

ASP5878, a selective FGFR inhibitor, to treat FGFR3‐dependent urothelial cancer with or without chemoresistance
por: Kikuchi, Aya, et al.
Publicado: (2017)

Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455
por: Wu, Daichao, et al.
Publicado: (2016)

Radiosensitization by the Selective Pan-FGFR Inhibitor LY2874455
por: Darwis, Narisa Dewi Maulany, et al.
Publicado: (2022)

Peritoneal Seeding Is More Common in Gastric Cancer Patients with FGFR2 Amplification or High Tumor Mutation Burden
por: Kim, Hyunjin, et al.
Publicado: (2022)

R-MPV followed by high-dose chemotherapy with thiotepa-based and autologous stem cell transplantation for newly diagnosed primary central nervous system lymphoma: a single-center experience
por: Lee, Ji Yun, et al.
Publicado: (2021)

Involvement of FGFR4 Gene Variants on the Clinicopathological Severity in Urothelial Cell Carcinoma
por: Tsay, Ming-Dow, et al.
Publicado: (2019)

Prognostic implications of FGFR1 and MYC status in esophageal squamous cell carcinoma
por: Kwon, Dohee, et al.
Publicado: (2016)

A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study
por: Choi, In Sil, et al.
Publicado: (2018)

FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder
por: Guancial, Elizabeth A, et al.
Publicado: (2014)

Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer
por: Garje, Rohan, et al.
Publicado: (2020)

FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer
por: Kacew, Alec, et al.
Publicado: (2020)

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models
por: Grünewald, Sylvia, et al.
Publicado: (2019)

Circular RNA circSMAD4 regulates cardiac fibrosis by targeting miR-671-5p and FGFR2 in cardiac fibroblasts
por: Jeong, Anna, et al.
Publicado: (2023)

Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement
por: Kwon, Ji-Hyun, et al.
Publicado: (2019)

A Real-World Efficacy of Nab-Paclitaxel Monotherapy in Metastatic Breast Cancer
por: Kim, Jung Sun, et al.
Publicado: (2022)

Paclitaxel as third-line chemotherapy for small cell lung cancer failing both etoposide- and camptothecin-based chemotherapy
por: Kim, Se Hyun, et al.
Publicado: (2017)

Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer
por: Shin, Junghoon, et al.
Publicado: (2019)

Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors
por: Qu, Lingzhi, et al.
Publicado: (2022)

A reciprocal regulatory circuit between CD44 and FGFR2 via c-myc controls gastric cancer cell growth
por: Park, Jihyun, et al.
Publicado: (2016)

3-Dimensional micropillar drug screening identifies FGFR2-IIIC overexpression as a potential target in metastatic giant cell tumor
por: Kim, Seung Tae, et al.
Publicado: (2017)

Clinical management and emerging therapies of FGFR3-related skeletal dysplasia in childhood
por: Kim, Hwa Young, et al.
Publicado: (2022)

Clinical characteristics and disease course of splanchnic vein thrombosis in gastrointestinal cancers: A prospective cohort study
por: Kang, Minsu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ud156umoqhp573gleftbjmidbd